Iambic Therapeutics is live · custom pricing · last verified 24 Oct 2026 · viability monitor
Iambic Therapeutics
Iambic Therapeutics pairs Enchant v3 and NeuralPLexer AI drug discovery models with a weekly wet lab and a wholly owned clinical pipeline.
Iambic earns attention because it can point at its own clinical readouts rather than a benchmark chart: IAM1363 in Phase 1/1b, IAM217 at IND as of October 2026, and AbbVie added to Bayer and Takeda as partners. If your program needs selective, brain-penetrant small molecules and you'd rather buy discovery execution than staff it, this is a credible door. If you want a tool you run yourself, or your modality isn't small molecules, it's the wrong door.
Verdict generatedVerified 6d ago · liveness 62/100 · cite: rightaichoice.com/tools/iambic-therapeutics
- Pharma R&D teams that want an end-to-end AI-to-clinic partner for small-molecule oncology
- Drug hunters targeting HER2, KIF18A, or CDK2/4 who need selective, brain-penetrant chemistry
- Companies holding a validated but stubborn target, including previously undruggable ones
- Funded biotechs that would rather outsource discovery execution than build models and a wet lab in-house
- Teams wanting off-the-shelf software to license, subscribe to, or call via API
- Biotechs working in biologics, gene therapy, or other non-small-molecule modalities
- Academic or low-budget researchers who need a free or low-cost tool to experiment with
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Iambic if you want to license or run the models yourself rather than pair with a clinical-stage oncology drug developer on a co-discovery program.
Iambic does not sell software seats or plans; participation is a co-discovery partnership with a clinical-stage, now publicly listed company. Budget for partnership economics — upfronts, milestones, and shared development cost — not a subscription. If you wanted a per-seat modeling tool, cheaper options exist; if you want a partner with its own clinical readouts and a weekly wet lab, that is what the partnership premium buys.
In short
Iambic Therapeutics — Iambic Therapeutics pairs Enchant v3 and NeuralPLexer AI drug discovery models with a weekly wet lab and a wholly owned clinical pipeline. Best for Pharma R&D teams that want an end-to-end AI-to-clinic partner for small-molecule oncology, Drug hunters targeting HER2, KIF18A, or CDK2/4 who need selective, brain-penetrant chemistry, Companies holding a validated but stubborn target, including previously undruggable ones. Pricing is on request (custom quotes).
No head-to-head comparison for Iambic Therapeutics yet — the alternatives below are the closest matches we list.
What is Iambic Therapeutics?
Iambic Therapeutics — Iambic Therapeutics pairs Enchant v3 and NeuralPLexer AI drug discovery models with a weekly wet lab and a wholly owned clinical pipeline. Best for Pharma R&D teams that want an end-to-end AI-to-clinic partner for small-molecule oncology, Drug hunters targeting HER2, KIF18A, or CDK2/4 who need selective, brain-penetrant chemistry, Companies holding a validated but stubborn target, including previously undruggable ones. Pricing is on request (custom quotes).
Iambic Therapeutics is an AI drug discovery company you partner with, not software you license. Its molecular superintelligence platform runs on two model families: Enchant, a multimodal transformer that links preclinical and clinical data, and NeuralPLexer, a co-folding model for protein-ligand binding prediction. Enchant v3 shipped September 21, 2026, built for end-to-end drug discovery and development rather than one design stage. The part rivals can't copy quickly is the lab. An AI-driven, high-throughput experimentation operation turns novel molecular designs into fresh biological data every week, which is what compresses the design-to-readout loop to days rather than quarters. Parallel optimization across multiple target product profiles and deep chemical space exploration support selective, brain-penetrant chemistry, including targets the industry has largely written off as undruggable. The proof is a wholly owned pipeline. IAM1363, a selective brain-penetrant HER2 inhibitor, has Phase 1/1b anti-tumor activity and tolerability data. IAM217, a brain-penetrant KIF18A inhibitor for ovarian cancer and triple-negative breast cancer, had its IND submitted October 5, 2026. IAM-C1, a selective CDK2/4 inhibitor for HR+/HER2- breast cancer and CCNE1 amplified cancers, sits at IND-enabling stage. Access runs through co-discovery partnerships instead of subscriptions: AbbVie signed in September 2026, joining Bayer and Takeda. The October 14, 2026 IPO pricing put Iambic on public markets. Oncology and CNS R&D groups weighing build-versus-partner should read this as the case for partnering with a clinical-stage shop and its data engine.
Key features
- Enchant v3 multimodal transformer for end-to-end drug discovery and development, launched September 21, 2026
- Enchant links preclinical and clinical data inside a single model
- NeuralPLexer co-folding model predicts protein-ligand binding
- AI-driven high-throughput experimentation lab generates new biological data weekly
- Weekly design-to-biological-readout cycle rather than quarterly
- Parallel optimization across multiple target product profiles
- Deep chemical space exploration to surface novel mechanisms of action
- Design of selective, brain-penetrant small-molecule inhibitors
- IAM1363 selective brain-penetrant HER2 inhibitor with Phase 1/1b anti-tumor activity and tolerability data
- IAM217 brain-penetrant KIF18A inhibitor for ovarian cancer and TNBC, IND submitted October 5, 2026
- IAM-C1 selective CDK2/4 inhibitor for HR+/HER2- and CCNE1 amplified cancers at IND-enabling stage
- End-to-end capability from target identification through clinical development
- Co-discovery partnership model with pharma partners including AbbVie, Bayer, and Takeda
Behind the verdict
Most AI drug discovery vendors sell you a model and wish you luck. Iambic's pitch is the opposite: hand us the target and we'll run design, synthesis, and biological readout ourselves, weekly. That's the real product — the Enchant and NeuralPLexer models are the engine, but the high-throughput lab is what makes the loop fast enough to matter.Pick Iambic when you have a validated but stubborn target, especially in oncology or CNS where blood-brain-barrier penetration is non-negotiable. The brain-penetrant chemistry across IAM1363, IAM217, and IAM-C1 is the clearest signal of what the platform actually does well. We'd also reach for it if you're a funded biotech that would rather outsource discovery execution than hire a modeling team and build a wet lab.Pass if you need software. Pass too if your modality is biologics, gene therapy, or anything outside small molecules — the whole stack is tuned for small-molecule design and optimization.The closest alternative is other clinical-stage AI-native biotechs with in-house labs, and the comparison comes down to pipeline evidence. Iambic's differentiator is that its clinical candidates were discovered on its own platform, so you're evaluating a track record, not a demo. The October 2026 IPO adds public scrutiny and disclosure, which cuts both ways: more visibility into the science, more pressure to hit milestones.Where it bites: partnerships mean shared control and negotiated IP terms, not a clean vendor relationship. Timelines run on Iambic's biology, not your roadmap. And a public company's priorities can shift with the quarterly cycle. Go in expecting a co-development partner with its own pipeline ambitions, because
Models under the hood
as of 2026-10-23
Limitations
- Iambic's platform is internal: Enchant v3 and NeuralPLexer are the company's own discovery engines, and the public material describes no external access — you cannot license the models, run the lab, or call an API.
- The pipeline is early: IAM1363 is in Phase 1/1b, IAM217 had its IND submitted on October 5, 2026, and IAM-C1 is still IND-enabling.
- Every disclosed program is a small-molecule oncology asset (HER2, KIF18A, CDK2/4), and the public record does not establish applicability outside that modality.
- The AbbVie, Bayer, and Takeda collaborations show the partnership route exists, but not what terms a given partner gets.
as of 2026-10-19
Researching Iambic Therapeutics? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Is Iambic Therapeutics still active?
Iambic Therapeutics is live · custom pricing · last verified 24 Oct 2026 · viability monitor.
Viability score
How well maintained and how widely used is Iambic Therapeutics? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: October 2026
How we score →What's new in Iambic Therapeutics
Checked 11 days agoAcross the latest 4 updates: 1 launch and 3 news mentions.
Iambic Announces Pricing of Initial Public Offering
Iambic Therapeutics priced its initial public offering, moving from private AI drug discovery company to public markets with the disclosure obligations that follow.
Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate
An IND was submitted for IAM217, a brain-penetrant KIF18A inhibitor aimed at ovarian cancer and triple-negative breast cancer — Iambic's second wholly owned AI-discovered candidate.
AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery
AbbVie signed a collaboration with Iambic to accelerate AI-driven drug discovery, joining Bayer and Takeda as pharma partners.
Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development
Enchant v3 released, positioned for end-to-end drug discovery and development rather than a single design stage of the workflow.
What do users say about Iambic Therapeutics?
What people actually say about Iambic Therapeutics — is it worth it?
We ran a structured research pass across product reviews, community discussions, and post-purchase forum threads to surface the patterns vendors won't publish themselves. Below: the recurring strengths, the hidden costs people mention most, and the cohort that consistently regrets adopting this tool.
ResearchedDiscussed by users across 1 source (YouTube) · researched Aug 21, 2026.
Average across the 1 source that answered — each source counts once, not each post.
- +End-to-end AI-to-clinic platform, a truly integrated approach.
- +Three clinical-stage candidates with brain-penetrant, selective designs.
- +Bayer collaboration signals external validation from a pharma giant.
- +CNBC Disruptor 50 recognition two years running bolsters credibility.
- +NeuralPLexer's co-folding model advances binding prediction accuracy.
- −No direct community feedback—reputation rests on marketing and press.
- −Enterprise-only offering locks out researchers and small startups.
- −Pricing opaque; likely prohibitive for most biotech teams.
- −No public API or software for hands-on evaluation.
- −Pipeline candidates early (Phase 1b), high clinical risk remains.
- • No public pricing—buyers must budget for long-term partnerships
- • Potential costs for clinical trial infrastructure and regulatory
- • Likely revenue-sharing or milestone payments
How we verified this
Every listed fact about Iambic Therapeutics— pricing, features, links, status — is re-read from the vendor's own pages by our verification pipeline and each change is logged with a date; the last pass ran on 24 Oct 2026. Pages mix model-assisted synthesis with human review; see how we verify.
Verification history
We have re-verified Iambic Therapeutics 21 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — changed description, summary, our verdict
- — changed limitations
- — changed switching in, limitations, description, summary, who should skip it, setup time, our verdict, pricing fit, features, switching out, hidden costs
- — changed who it suits, features, our verdict, description, summary
- — changed limitations, pricing page
- — changed who it suits, summary, description, our verdict, features, who should skip it
Showing the 6 most recent of 21 verification passes.
Free to cite with attribution — this page re-verifies continuously.
How much does Iambic Therapeutics cost in 2026?
Iambic Therapeutics: Pricing is on request (custom quotes). Pricing last verified 24 Oct 2026.
Where the pricing makes sense
The company stage and team size where Iambic Therapeutics's pricing actually pencils out — and where peers do it cheaper.
Iambic does not sell software seats or plans; participation is a co-discovery partnership with a clinical-stage, now publicly listed company. Budget for partnership economics — upfronts, milestones, and shared development cost — not a subscription. If you wanted a per-seat modeling tool, cheaper options exist; if you want a partner with its own clinical readouts and a weekly wet lab, that is what the partnership premium buys.
Has Iambic Therapeutics' pricing changed?
No plan price for Iambic Therapeutics has moved since we began logging in Aug 2026; the pricing page is re-read on every verification pass.
Who should pick Iambic Therapeutics?
Pick Iambic Therapeutics if you are Pharma R&D teams that want an end-to-end AI-to-clinic partner for small-molecule oncology, Drug hunters targeting HER2, KIF18A, or CDK2/4 who need selective, brain-penetrant chemistry, Companies holding a validated but stubborn target, including previously undruggable ones, Funded biotechs that would rather outsource discovery execution than build models and a wet lab in-house.
Look elsewhere if you are Teams wanting off-the-shelf software to license, subscribe to, or call via API, Biotechs working in biologics, gene therapy, or other non-small-molecule modalities, Academic or low-budget researchers who need a free or low-cost tool to experiment with, Groups that must retain full control of every discovery step and all associated IP.
Skip it if Skip Iambic if you want to license or run the models yourself rather than pair with a clinical-stage oncology drug developer on a co-discovery program.
GeneratedReal-world workflow fit
Concrete scenarios for the personas Iambic Therapeutics actually fits — and what changes day-one when you adopt it.
You hold a validated kinase target but prior leads failed on selectivity and brain penetration. You scope a co-discovery partnership, hand over target biology, and work with Iambic's drug hunters on designs that route through their high-throughput lab for weekly biological readout.
Outcome: Design cycles compress from quarters to weeks, and you get real binding and cellular data each round rather than predicted data, with IAM1363's Phase 1/1b results as the reference case for what the loop produces.
You have capital and a target but no in-house modeling team or high-throughput lab. Rather than hire a computational chemistry group and build wet-lab capacity, you structure a partnership and let Iambic's Enchant and NeuralPLexer stack plus the weekly experimentation engine carry discovery execution.
Outcome: You reach candidate selection without owning the infrastructure, at the cost of sharing program economics and control — the same trade AbbVie, Bayer, and Takeda made.
You screen partner options for chemistry that reliably crosses the BBB. You point to IAM1363 (brain-penetrant HER2) and IAM217 (brain-penetrant KIF18A) as evidence the platform optimizes for penetration rather than treating it as an afterthought.
Outcome: You shortlist Iambic against model-only vendors that cannot show a brain-penetrant clinical candidate, and you go into diligence knowing the evidence is early-stage.
Use cases
- Design novel small-molecule inhibitors for oncology targets where selectivity and brain penetration are hard requirements
- Optimize lead compounds for improved safety, efficacy, and pharmacokinetic profiles
- Attack known but difficult targets, including ones previously treated as undruggable
- Compress preclinical discovery so molecular designs reach biological validation in weeks rather than quarters
- Co-discover and co-develop therapeutic candidates with Iambic under a pharma-style partnership
- Generate first-in-class or best-in-class leads for oncology indications such as HER2-driven, KIF18A, and CDK2/4 cancers
Setup time & first value
How long it actually takes to get something useful out of Iambic Therapeutics — broken out by persona, not the marketing-page minute.
Expect scoping and legal negotiation measured in months before any design work starts; once a program is agreed, the weekly design-to-readout cadence is the operating rhythm. Biotech partners with a defined target and clean data room move fastest.
Switching to or from Iambic Therapeutics
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From a model-only AI vendor: move the target to Iambic when you need wet-lab validation each week, since Enchant and NeuralPLexer sit alongside the company's own high-throughput experimentation rather than standing
- →From a CRO-led discovery campaign: replace outsourced chemistry rounds with a co-discovery partnership where designs feed a weekly biological readout loop.
- ↗To an in-house discovery group: exit is contractual, so negotiate IP and data rights at signing; nothing public describes a data export path from the internal platform.
Resources & guides
Tutorials & Learning
Iambic Therapeutics: Inside the Company Advancing and Accelerating AI in Drug Development
Freeflow Ventures
We visited Iambic Therapeutics in San Diego and learned how they are using AI in drug discovery.
BiotechTV
Revolutionizing Drug Discovery with AI: Fred Manby of Iambic Therapeutics
CorrDyn
YouTube returned 6 videos for “Iambic Therapeutics”, and we withheld 1: 1 did not mention Iambic Therapeutics. Showing the 5 we can prove are about Iambic Therapeutics.
Official links
What are the best Iambic Therapeutics alternatives?
The closest alternatives to Iambic Therapeutics we list are Isomorphic Labs, Insilico Medicine and Recursion. Ranked by direct product-type match, not category overlap.
| Alternative | Pricing | Starts at | Last verified |
|---|---|---|---|
| Isomorphic Labs | Contact Sales | Custom pricing | — |
| Insilico Medicine | Contact Sales | Custom pricing | — |
| Recursion | Contact Sales | Custom pricing | — |
Alternatives to Iambic Therapeutics
View all
Isomorphic Labs
AI drug discovery from Isomorphic Labs: predictive and generative models that design molecules and forecast drug performance.
Insilico Medicine
Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.
Tools that pair well with Iambic Therapeutics
Common stack mates teams adopt alongside Iambic Therapeutics, with the specific reason each pairing earns its keep.
Isomorphic Labs
AI drug discovery from Isomorphic Labs: predictive and generative models that design molecules and forecast drug performance.
Insilico Medicine
Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.
Recursion
AI drug discovery driven by a wet-and-dry lab-in-the-loop that runs millions of weekly cell experiments.
Frequently asked questions
Categories
Topics
Used Iambic Therapeutics? Help shape our editorial sentiment research.